Medical Device News Magazine

SyncThink Secures CE Mark for EYE-SYNC Digital Health Platform

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

SyncThink, a next generation neurotechnology company, and makers of the award-winning EYE-SYNC technology, announces today that it has completed CE Mark certification, affirming conformity to European Medical Device Regulation (MDR), also known as ISO 13485. EYE-SYNC will be registered as a Class I medical device.

“The CE Mark authorization for EYE-SYNC is a tremendous advancement in our commitment to bringing objective, reliable measures of neurological function to healthcare providers in Europe,” said SyncThink CEO Gary Gregory. “We are excited to expand our commercial opportunities and strengthen our position in the market, while making our product more accessible to patients everywhere.”

The new certification allows for commercialization of EYE-SYNC in the European Union (EU) and the United Kingdom (UK), expanding opportunities for new business development and distribution in applicable nations. Providers in these areas will be able to purchase and implement the EYE-SYNC system beginning this month, utilizing the most recent version of EYE-SYNC that comes equipped on PicoXR’s Neo 3 Pro Eye.

The CE Mark is the latest advancement among a series of growth announcements for the company. In addition to the PicoXR partnership, SyncThink recently announced the expansion of their clinical advisory board, shortly after receiving their second FDA clearance for EYE-SYNC as an Aid to Concussion Diagnosis or mild Traumatic Brain injury (mTBI). Earlier this year, SyncThink was selected by Augmented Reality (AR) leader Magic Leap as a partner in their efforts to expand into healthcare worldwide.

The EYE-SYNC technology combines proprietary software and data analytics with high performance eye tracking sensors to measure and quantify eye movement biomarkers reflective of neurological impairment or disease. It is currently used by healthcare providers in hospitals and rehabilitation centers, sports, military, and in CNS drug development around the world.
The Conformitè Europëenne (CE) Mark confirms the manufacturer’s goods conform with European health, safety, and environmental protection standards.

It is defined as the European Union’s (EU) mandatory conformity marking for regulating the goods sold within the European Economic Area (EEA) since 1985. The CE marking represents a manufacturer’s declaration that products comply with the EU’s New Approach Directives. These directives not only apply to products within the EU but also for products that are manufactured in or designed to be sold in the EEA. This makes the CE marking recognizable worldwide even to those unfamiliar with the EEA.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”